证券代码：688677 证券简称：海泰新光 公告编号：2023-042 青岛海泰新光科技股份有限公司 第三届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 监事会认为：公司本次作废处理部分限制性股票符合有关法律、法规及公司 2022 年限制性股票激励计划的相关规定，不存在损害股东利益的情况，监事会 同意公司此次作废处理部分限制性股票。 表决结果：同意3票，反对0票，弃权0票。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《关于作废处理2022年限制性股票激励计划部分限制性股票的公告》（公告编号： 2023-043）。 （二）审议通过《关于公司2022年限制性股票激励计划第一个归属期符合 归属条件的议案》 监事会认为：公司2022年限制性股票激励计划授予的限制性股票第一个归属 期的归属条件已经成就，同意符合归属条件的120名激励对象归属51.7496万股限 制性股票，本事项符合《上市公司股权激励管理办法》、《2022年限制性股票激励 计 ...

根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关规定，现将公司回购股份的进展公告如下： 截至 2023 年 8 月 31 日，青岛海泰新光科技股份有限公司（以下简称"公司"） 通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份 618,452 股，占公司总股本121,637,381股的比例为0.5084%，回购成交的最高价为60.36 元/股，最低价为 48.39 元/股，支付的资金总额为人民币 32,911,830.87 元（不 含印花税、交易佣金等交易费用）。 三、其他事项 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、回购股份的基本情况 公司于 2023 年 6 月 15 日召开第三届董事会第十三次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》（以下简称"本次回购方案"）， 同意公司以自有资金通过上海证券交易所交易系统以集中竞价交易方式回购公 司已发行的部分人民币普通股股票。回购的股份将在未来适宜时机全部用于员工 持股计划或股权激励，回购 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, achieving a total of 500 million yuan, representing a growth of 25% year-over-year[16]. - The company's operating revenue for the first half of 2023 reached ¥267,805,459.78, representing a 36.48% increase compared to ¥196,229,758.14 in the same period last year[20]. - The net profit attributable to shareholders increased by 11.85% to ¥89,332,980.19 from ¥79,869,433.79 year-on-year[20]. - The net profit after deducting non-recurring gains and losses grew by 17.32% to ¥85,718,697.38, with a significant impact from share-based payments and losses from investments in joint ventures[23]. - The net cash flow from operating activities increased by 20.57% to ¥80,938,274.66, driven by higher sales collections[23]. - Basic earnings per share rose by 12.12% to ¥0.74, while diluted earnings per share increased by 10.61% to ¥0.73[21]. - The company's main business revenue from medical endoscopes was CNY 211.25 million, accounting for 79.19% of main business revenue, with a year-on-year growth of 46.26%[99]. - The optical products revenue was CNY 55.53 million, representing 20.81% of main business revenue, with a year-on-year increase of 7.34%[99]. Research and Development - The company is investing in R&D, allocating 10% of its revenue towards developing new technologies and enhancing existing products[16]. - Research and development expenses accounted for 12.87% of operating revenue, up from 12.27% in the previous year[22]. - The company reported a research and development investment of approximately ¥34.47 million, representing a 43.17% increase compared to ¥24.08 million in the same period last year, with R&D expenses accounting for 12.87% of total revenue[83]. - The number of R&D personnel has increased to 131, representing 16.31% of the total workforce, up from 14.17% in the previous year[91]. - The total compensation for R&D personnel has risen to ¥2,347.71 million, with an average salary of ¥17.92 million per person[91]. - The company has filed 16 new patent applications and received 21 new patent grants during the reporting period, including patents for thoracoscopic endoscopes and 4K endoscopic imaging systems[80]. Product Development and Innovation - New product launches include an advanced medical imaging device, expected to contribute an additional 100 million yuan in revenue by the end of the year[16]. - The company has developed a range of medical endoscope products, including 4K fluorescence/white light laparoscopes and various specialized endoscopes, enhancing its product line in the medical optical imaging field[34]. - The company has successfully developed a dual-path 3D fluorescence endoscope technology, which can be used in 10mm 3D laparoscopic systems, enhancing surgical capabilities[76]. - The company is developing new products including 3D endoscope imaging systems and consumer-level palm vein modules[100]. - The company has achieved a FAR (False Acceptance Rate) of 0.00001% for its palm vein recognition technology, indicating high accuracy in identity verification[87]. Market Expansion and Strategy - User data indicates that the active user base has expanded to 1.2 million, marking a 15% increase compared to the previous period[16]. - Market expansion efforts have led to the establishment of two new distribution partnerships in Southeast Asia, aiming to increase market share by 30% in that region[16]. - The company has set a revenue guidance for the second half of 2023, projecting an increase of 20% to reach approximately 600 million yuan[16]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies specializing in medical technology[16]. - The company is expanding its marketing network and information technology projects to enhance market competitiveness and sales capabilities[104]. Operational Efficiency - A new strategic initiative has been introduced to improve operational efficiency, targeting a reduction in production costs by 15% over the next year[16]. - The company has implemented the ISO 13485 quality management system for medical devices, ensuring compliance with global quality management requirements[98]. - The gross profit margin is under pressure due to a higher growth rate in operating costs (43.25%) compared to revenue growth (36.48%)[112]. Financial Position and Assets - The company's total assets at the end of the reporting period were ¥1,380,614,575.77, a slight decrease of 0.93% from the previous year[20]. - Cash and cash equivalents decreased by 43.55% to 359,125,999.09, accounting for 26.01% of total assets, down from 45.65% last year[116]. - Trade financial assets increased by 100% to 260,939,152.93, representing 18.90% of total assets[116]. - Accounts receivable decreased by 19.21% to 92,361,271.92, accounting for 6.69% of total assets[116]. - Inventory increased by 13.85% to 157,121,781.51, representing 11.38% of total assets[116]. Shareholder Commitments and Governance - The company has committed to a share lock-up period of 36 months from the date of stock listing, during which no shares can be transferred or managed by others[138]. - The company’s major shareholders and actual controllers have made commitments to not propose repurchase of shares during the lock-up period[140]. - The company’s management must report any changes in their shareholdings to the stock exchange[142]. - The company has outlined specific procedures for disclosing share reduction plans to ensure transparency[142]. - The commitments made by the company’s shareholders are binding and cannot be altered due to changes in their positions[141]. Environmental and Social Responsibility - The company has established an environmental protection mechanism, with an investment of 0 million in environmental protection during the reporting period[129]. - The company does not belong to the list of key pollutant discharge units and is not classified as a heavily polluting enterprise[131]. - Wastewater is treated through a septic tank and then discharged into the municipal sewage system after meeting standards[131]. - The company employs measures to control dust and non-methane total hydrocarbon emissions during production processes[132]. - Solid waste is managed through collection and treatment by qualified hazardous waste disposal companies[132].

证券代码：688677 证券简称：海泰新光 公告编号：2023-038 青岛海泰新光科技股份有限公司 第三届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 青岛海泰新光科技股份有限公司（以下简称"公司"）第三届监事会第十一 次会议于 2023 年 8 月 28 上午 11:00 在公司会议室召开，会议通知已于 2023 年 8 月 17 日以邮件方式送达。公司监事 3 人，实际参会监事 3 人。会议由公司监事 会主席郑今兰女士主持，会议的召集和召开程序符合《中华人民共和国公司法》 和《公司章程》等相关规定，会议形成的决议合法、有效。 二、监事会会议审议情况 经与会监事投票表决，审议通过了如下议案： （一）《关于<公司 2023 年半年度报告>及摘要的议案》 （二）《关于<公司 2023 年半年度募集资金存放与使用情况专项报告>的议 案》 公司监事会认为：公司《2023 年半年度募集资金存放与实际使用情况专项 报告》在所有重大方面符合《上市公司监管指引第 2 号——上市公司 ...

一、关于公司《2023 年半年度募集资金存放与使用情况专项报告》的独立 意见 青岛海泰新光科技股份有限公司 独立董事对第三届董事会第十四次会议相关事项的 独立意见 根据《青岛海泰新光科技股份有限公司章程》和有关法律法规的规定，我们 作为青岛海泰新光科技股份有限公司（以下简称"公司"）的独立董事，对第三 届董事会第十四次会议的议案进行了认真审议，对需要独立董事发表独立意见的 相关议案发表独立意见如下： （本页无正文，为《青岛海泰新光科技股份有限公司独立董事关于公司第三届董 事会第十四次会议相关事项的独立意见》的签署页之三） 经核查，我们认为：公司2023年度半年度募集资金存放和实际使用符合《上 市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》《上海证 券交易所上市公司募集资金管理办法（2013年修订）》等相关法律法规和规范性 文件的规定。公司所披露的募集资金存放和使用情况信息与实际情况相符，不存 在变相改变募集资金用途、违规存放与使用募集资金的情形，也不存在损害公司 及股东,尤其是中小股东利益的情形。综上，我们同意关于公司《2023年半年度 募集资金存放与使用情况专项报告》的议案。 张自力 ZIL ...

证券代码：688677 证券简称：海泰新光 公告编号：2023-039 青岛海泰新光科技股份有限公司 关于公司募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》、《上海证券交易所科创板股票上市规则》和《上海证券 交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，青岛海 泰新光科技股份有限公司（以下简称"公司"）董事会对 2023 年半年度募集资 金存放与实际使用情况专项报告说明如下： 一、募集资金基本情况 （一）经上海证券交易所科创板股票上市委员会 2020 年 9 月 29 日审核同意， 并经中国证券监督管理委员会 2021 年 1 月 12 日《关于同意青岛海泰新光科技股 份有限公司首次公开发行股票注册的批复》（证监许可[2021]90 号）核准，同 意本公司公开发行人民币普通股 21,780,000 股，发行价格为人民币 35.76 元/ 股。募集资金总额为人民币 77 ...

国泰君安证券股份有限公司 关于青岛海泰新光科技股份有限公司 2023 年半年度持续督导跟踪报告 国泰君安证券股份有限公司（以下简称"国泰君安"或"保荐机构"）作为青岛 海泰新光科技股份有限公司（以下简称"海泰新光"或"公司"）首次公开发行股票 并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》、《上海证 券交易所科创板股票上市规则》、《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等相关规定，负责海泰新光上市后的持续督导工作，并出具本 持续督导跟踪报告。 | 一、持续督导工作情况 | | --- | | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导业务管理制 | 保荐机构已建立健全并有效执行持 续督导工作制度，并制作了相应的 | | 1 | 度；制作并保存持续督导工作底稿 | | | | | 持续督导工作底稿 | | 2 | 建立健全保荐代表人工作制度，明确保荐代 表人的工作要求和职责，建立有效的考核、 | 保荐机构已建立健全并有效执行保 | | | | 荐代表人工作制度 | | | 激励和约束机制 在持续督导期 ...

股票代码：688677 股票简称：海泰新光 公告编号：2023-037 青岛海泰新光科技股份有限公司 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 08 月 22 日(星期二) 至 08 月 28 日(星期一)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 investment@novelbeam.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 青岛海泰新光科技股份有限公司（以下简称"公司"）将于 2023 年 8 月 29 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年上半年经营成果、财务状况，公司计划于 2023 年 08 月 29 日下午 16:00-17:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年上半年经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、回购股份的基本情况 公司于 2023 年 6 月 15 日召开第三届董事会第十三次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》（以下简称"本次回购方案"）， 同意公司以自有资金通过上海证券交易所交易系统以集中竞价交易方式回购公 司已发行的部分人民币普通股股票。回购的股份将在未来适宜时机全部用于员工 持股计划或股权激励，回购价格不超过 90 元/股（含），回购资金总额不低于人 民币 3,000 万元（含），不超过人民币 6,000 万元（含），回购期限自公司董事 会审议通过本次回购方案之日起 12 个月内。具体内容详见公司于 2023 年 6 月 16 日在上海证券交易所网站（www.sse.com.cm）上披露的《青岛海泰新光科技 股份有限公司关于以集中竞价交易方式回购股份方案的公告》（公告编号： 2023-027）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关规定，现将公司回 ...

Financial Performance - The company's operating revenue for 2022 reached ¥476,821,312.39, representing a year-on-year increase of 53.97%[24]. - Net profit attributable to shareholders increased by 55.07% to ¥182,569,601.64, while the net profit excluding non-recurring gains and losses rose by 79.44% to ¥168,680,318.38[24][27]. - The cash flow from operating activities remained stable, with a net amount of ¥104,375,771.45, showing a slight increase of 0.36% compared to the previous year[24][27]. - Total assets grew by 17.92% to ¥1,393,534,642.98, and net assets attributable to shareholders increased by 11.75% to ¥1,219,243,201.94[24][27]. - Basic earnings per share rose to ¥2.10, reflecting a 48.94% increase from the previous year[25]. - The company's operating income for the fourth quarter was 137,148,352.30 RMB, while the net profit attributable to shareholders was 42,692,243.69 RMB, indicating a stable performance despite fluctuations in net profit due to factors such as share-based payments and exchange rate losses[30][31]. Dividend and Capital Structure - The company plans to distribute a cash dividend of RMB 8.00 per 10 shares, totaling RMB 69,314,761.60 (including tax) based on the remaining shares after buybacks[5]. - The company intends to increase its capital reserve by issuing 4 additional shares for every 10 shares held, resulting in an increase of 34,657,381 shares, raising the total share capital to 121,637,381 shares[5]. - The company has not experienced any changes in its total share capital from the announcement date to the equity distribution registration date[6]. Audit and Governance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[5]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[9]. - The company has not violated any decision-making procedures for external guarantees[9]. - The company has not disclosed any special arrangements for corporate governance[9]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors[8]. Research and Development - The company's R&D expenditure accounted for 12.56% of operating revenue, a decrease of 0.79 percentage points compared to 2021[25]. - Research and development investment in 2022 was 59.90 million yuan, a 44.88% increase from the previous year, constituting 12.56% of operating revenue[40]. - The company applied for 42 new patents and obtained 33 new patents during the reporting period[118]. - The company has a cumulative total of 156 patent applications, with 96 patents granted, reflecting its commitment to innovation[119]. - The company has developed a dual-channel 3D fluorescence endoscope technology suitable for 10mm laparoscopic systems, enhancing surgical capabilities[115]. Market and Sales - The company achieved dual growth in both domestic and international markets while expanding its optical business and related products alongside the rapid growth of its medical endoscope business[38]. - The company plans to increase the promotion of its complete system products domestically, despite facing competition from established imported brands[136]. - The total sales revenue for the top five customers reached 375.19 million RMB, accounting for 78.69% of the annual sales total[157]. - Sales to Customer 1 amounted to 295.44 million RMB, representing 61.96% of the annual sales total, with a year-on-year increase of 67.41%[158]. Production and Supply Chain - The company has increased inventory to mitigate the impact of extended delivery times due to global supply chain disruptions[54]. - The company implements a supply chain management system that includes supplier grading and continuous evaluation to ensure quality[51]. - The production of medical endoscopes follows ISO 13485 standards, ensuring compliance with quality management requirements[54]. - The company has seen an increase in procurement from new suppliers due to increased production of new products[163]. Technological Innovation - The company has established four core technology platforms: optical technology, precision machinery technology, electronic technology, and digital image technology[76]. - The company has successfully implemented multi-spectral LED illumination technology in endoscope systems, which can also be extended to clinical diagnostic applications[81]. - The company has developed a leading fluorescence endoscope that integrates fluorescence technology with endoscopic technology, opening new applications in the medical field[74]. - The company is integrating deep learning-based intelligent image recognition technology into its next-generation intelligent surgical endoscope system[75]. Future Plans - The company plans to accelerate the development of medical endoscope series products to expand its existing product line[182]. - The company aims to enhance its competitive edge in fluorescence endoscope products by continuously upgrading existing models and developing new ones[184]. - The company is committed to strengthening talent development and improving employee cohesion through a competitive compensation system[192]. - The company will complete the registration and launch of the second generation 4K fluorescence endoscope imaging system and fog-free imaging system, establishing a nationwide distribution channel[194].